The Analytical Tools to Objectively Measure Human Performance (ATOM-HP) program is a two year pilot project between the National Cancer Institute’s Center for Strategic Initiatives and the... Read More
A new USC-led initiative unites national cancer and defense resources in pursuit of a common goal: a quantitative way to determine just how healthy a patient is.
The project, dubbed Analytical Tools to Objectively Measure Human Performance (ATOM-HP), will create a high-quality performance status tracking system for cancer patients during therapy and long-term follow-up.
This program is a joint effort of the National Cancer Institute’s Center for Strategic Initiatives and the Department of Defense’s Rapid Reaction Technology Office.
The work entitled “SPATIOTEMPORAL PROGRESSION OF METASTATIC BREAST CANCER: A MARKOV CHAIN MODEL HIGHLIGHTING THE ROLE OF EARLY METASTATIC SITES” by Paul K. Newton and colleagues is the featured article in the last edition of npj Breast Cancer.
In this study, the authors found that spatiotemporal patterns of metastatic spread in breast cancer are neither random nor unpredictable and developed a Markov based model of breast cancer progression that has predictive capability. They used data from 446 patients, collected over several decades, to create a probability model that can predict patient survival according to the first site of metastasis. They propose that sites can be classified as ‘spreaders’ or ‘sponges’ on the basis of whether the cancer is likely to spread further. The model could help physicians to provide better prognoses and facilitate research into the biology of metastasis. The authors suggest that future models might also incorporate how therapy type and tumor size influence metastasis and survival.
npj Breast Cancer is a multidisciplinary research journal, published in partnership between the Breast Cancer Research Foundation (BCRF) and Nature Publishing Group (NPG).
Our own Breast Cancer Research Foundation (BCRF) researchers, Dr. Peter Kuhn and Dr. James Hicks, are featured in the Huffington Post. The liquid biopsy developed in the Kuhn-Hicks laboratory at the Bridge Institute at USC is an enabling technology that will improve risk assessment and individualized therapies for breast cancer patients.
From the article: "One of the most promising frontiers for precision medicine is research in metastatic breast cancer. The Breast Cancer Research Foundation has long supported research into ways we can improve diagnosis, individual therapies and - ultimately - prevention."
When President Obama announced his Precision Medicine Initiative, it was a new concept to many, but not to those of us involved in metastatic breast cancer research. To us, the call was a signal of a new commitment with the potential to advance the progress that has been made.
October is Breast Cancer Awareness Month.
The Breast Cancer Awareness Month, marked in countries across the world every October, helps to increase attention and support for the awareness, early detection and treatment as well as palliative care of this disease.
Ductal carcinoma in situ (DCIS) is a stage 0 breast cancer that has been in the news of late because many cancer doctors are rethinking the way it should be treated. Shelley Hwang, MD, a Duke breast surgeon and our collaborator for more than 5 years, has been at the forefront of these discussions. In the October 12, 2015 issue of TIME magazine, Hwang joins other leading breast cancer doctors in explaining why women have been massively over-treated for this type of breast cancer, often being told they need extensive radiation, chemotherapy. Some even opt to undergo mastectomy to reduce their anxiety.
Dr. Hwang said new research shows active surveillance – following the cancer closely with regular screenings – may be a better approach for some women.